{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:37:18Z","timestamp":1786541838181,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,12]]},"DOI":"10.7759\/cureus.114411","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:02:27Z","timestamp":1786539747000},"source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin Taper-and-Pulse Therapy for Recurrent Clostridioides difficile Infection in Pediatric Acute Lymphoblastic Leukemia Patients Treated With Blinatumomab and Chemotherapy: A Report of Three Cases"],"prefix":"10.7759","author":[{"given":"Haiyan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103371","article-title":"Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10)","volume":"87","author":"Mikulska M","year":"2025","unstructured":"Mikulska M, Robin C, Neofytos D, et al.. Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10). EClinicalMedicine. 2025, 87:103371. 10.1016\/j.eclinm.2025.103371","journal-title":"EClinicalMedicine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13173","article-title":"A contemporary review of Clostridioides difficile infections in patients with haematologic diseases","volume":"289","author":"Dutta D","year":"2021","unstructured":"Dutta D, Jafri F, Stuhr D, Knoll BM, Lim SH. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. J Intern Med. 2021, 289:293-308. 10.1111\/joim.13173","journal-title":"J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102604","article-title":"Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update","volume":"72","author":"Patel P","year":"2024","unstructured":"Patel P, Robinson PD, Fisher BT, et al.. Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update. EClinicalMedicine. 2024, 72:102604. 10.1016\/j.eclinm.2024.102604","journal-title":"EClinicalMedicine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac138","article-title":"Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?","volume":"5","author":"Patel D","year":"2023","unstructured":"Patel D, Senecal J, Spellberg B, et al.. Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?. JAC Antimicrob Resist. 2023, 5:dlac138. 10.1093\/jacamr\/dlac138","journal-title":"JAC Antimicrob Resist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.60495","article-title":"Initial vancomycin taper-pulse regimen for recurrent Clostridioides difficile infection: a randomized clinical trial","volume":"9","author":"McDonald EG","year":"2026","unstructured":"McDonald EG, Butler-Laporte G, Brophy JM, et al.. Initial vancomycin taper-pulse regimen for recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA Netw Open. 2026, 9:e2560495. 10.1001\/jamanetworkopen.2025.60495","journal-title":"JAMA Netw Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S348501","article-title":"The clinical efficacy, safety, and tolerability of vancomycin for the treatment of recurrent Clostridioides difficile infection: a systematic review","volume":"15","author":"Knudsen MJ","year":"2023","unstructured":"Knudsen MJ, Rubin IM, Petersen AM. The clinical efficacy, safety, and tolerability of vancomycin for the treatment of recurrent Clostridioides difficile infection: a systematic review. Drug Healthc Patient Saf. 2023, 15:63-71. 10.2147\/DHPS.S348501","journal-title":"Drug Healthc Patient Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw731","article-title":"Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial","volume":"64","author":"Hota SS","year":"2017","unstructured":"Hota SS, Sales V, Tomlinson G, et al.. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017, 64:265-71. 10.1093\/cid\/ciw731","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00135-23","article-title":"Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options","volume":"37","author":"Di Bella S","year":"2024","unstructured":"Di Bella S, Sanson G, Monticelli J, et al.. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev. 2024, 37:e0013523. 10.1128\/cmr.00135-23","journal-title":"Clin Microbiol Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald LC","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, et al.. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018, 66:e1-e48. 10.1093\/cid\/cix1085","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly CR","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021, 116:1124-47. 10.14309\/ajg.0000000000001278","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023062307","article-title":"Clostridioides difficile infection in children: recent updates on epidemiology, diagnosis, therapy","volume":"152","author":"Shirley DA","year":"2023","unstructured":"Shirley DA, Tornel W, Warren CA, Moonah S. Clostridioides difficile infection in children: recent updates on epidemiology, diagnosis, therapy. Pediatrics. 2023, 152:e2023062307. 10.1542\/peds.2023062307","journal-title":"Pediatrics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00407","article-title":"Guideline for the management of clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients","volume":"36","author":"Diorio C","year":"2018","unstructured":"Diorio C, Robinson PD, Ammann RA, et al.. Guideline for the management of clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2018, 36:3162-71. 10.1200\/JCO.18.00407","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1149","article-title":"Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE)","volume":"71","author":"Wolf J","year":"2020","unstructured":"Wolf J, Kalocsai K, Fortuny C, et al.. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis. 2020, 71:2581-8. 10.1093\/cid\/ciz1149","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv453","article-title":"Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model","volume":"71","author":"Crowther GS","year":"2016","unstructured":"Crowther GS, Chilton CH, Longshaw C, et al.. Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model. J Antimicrob Chemother. 2016, 71:986-91. 10.1093\/jac\/dkv453","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001411","article-title":"Intensity of therapy for malignancy and risk for recurrent and complicated Clostridium difficile infection in children","volume":"41","author":"Willis ZI","year":"2019","unstructured":"Willis ZI, Nicholson MR, Esbenshade AJ, et al.. Intensity of therapy for malignancy and risk for recurrent and complicated Clostridium difficile infection in children. J Pediatr Hematol Oncol. 2019, 41:442-7. 10.1097\/MPH.0000000000001411","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2018.029","article-title":"Infectious risks and complications in adult leukemic patients receiving blinatumomab","volume":"10","author":"So W","year":"2018","unstructured":"So W, Pandya S, Quilitz R, Shah B, Greene JN. Infectious risks and complications in adult leukemic patients receiving blinatumomab. Mediterr J Hematol Infect Dis. 2018, 10:e2018029. 10.4084\/MJHID.2018.029","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611701","article-title":"Blinatumomab in pediatric B-acute lymphoblastic leukemia","volume":"16","author":"Cheng Y","year":"2025","unstructured":"Cheng Y, Liu A. Blinatumomab in pediatric B-acute lymphoblastic leukemia. Front Immunol. 2025, 16:1611701. 10.3389\/fimmu.2025.1611701","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517885-vancomycin-taper-and-pulse-therapy-for-recurrent-clostridioides-difficile-infection-in-pediatric-acute-lymphoblastic-leukemia-patients-treated-with-blinatumomab-and-chemotherapy-a-report-of-three-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:02:28Z","timestamp":1786539748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517885-vancomycin-taper-and-pulse-therapy-for-recurrent-clostridioides-difficile-infection-in-pediatric-acute-lymphoblastic-leukemia-patients-treated-with-blinatumomab-and-chemotherapy-a-report-of-three-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.114411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}